{
	"kja6ijk1Text": "Th<span class=\"_ _2\"></span>e ma<span class=\"_ _2\"></span>jo<span class=\"_ _c\"></span>rit<span class=\"_ _0\"></span>y of pa<span class=\"_ _c\"></span>t<span class=\"_ _0\"></span>ie<span class=\"_ _c\"></span>nt<span class=\"_ _0\"></span>s rec<span class=\"_ _c\"></span>eiv<span class=\"_ _c\"></span>ed<br>Br<span class=\"_ _2\"></span>in<span class=\"_ _2\"></span>tel<span class=\"_ _c\"></span>lix<span class=\"_ _2\"></span>® 2<span class=\"_ _2\"></span>0 mg i<span class=\"_ _2\"></span>n fle<span class=\"_ _c\"></span>xib<span class=\"_ _2\"></span>le d<span class=\"_ _2\"></span>os<span class=\"_ _c\"></span>e s<span class=\"_ _0\"></span>tudi<span class=\"_ _2\"></span>es<span class=\"_ _3\"></span><span class=\"fs1 ls2 ws0 v1\">1-<span class=\"_ _1\"></span>4</span>",
	"kja6ijk2Text": "<div style=\"text-align: justify;\"><span style=\"font-size: 13.409px; letter-spacing: 0px; word-spacing: -0.013409px; -webkit-text-stroke: 0.015em transparent;\">†</span><span class=\"fsb lsd ws1f v5\" style=\"-webkit-text-stroke: 0.015em transparent;\">The change from baseline to week 8 in DSS<span class=\"_ _2\"></span>T performance score was significantly dif<span class=\"_ _2\"></span>ferent for vortioxetine (n=168) vs.<span class=\"_ _c\"></span> placebo (n=164;  +1.75, 95% CI: 0.28, 3.21; </span></div><div style=\"text-align: justify;\"><span style=\"-webkit-text-stroke: 0.015em transparent; font-size: 23px; letter-spacing: -0.23px; word-spacing: -0.529px;\">p=</span><span class=\"ws20\" style=\"-webkit-text-stroke: 0.015em transparent; font-size: 23px; letter-spacing: -0.23px;\">0.019; ANCO<span class=\"_\"> </span>VA,<span class=\"_ _2\"></span> OC), with a standardised ef<span class=\"_ _2\"></span>fect size of 0.254, but not for duloxetine (n=176) vs.<span class=\"_\"> </span> placebo ( +1.21, 95% CI: −0.23,<span class=\"_ _2\"></span> 2.65; p=0.099), with a standardised </span></div><div><span class=\"fsb lsd ws1f v5\"><div style=\"text-align: justify;\"><span style=\"word-spacing: -0.989px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">effect size of 0.176; </span><span class=\"fs10 ls5 ws1d v6\" style=\"-webkit-text-stroke: 0.015em transparent;\">‡</span><span style=\"word-spacing: -0.989px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">Pr</span><span class=\"_ _2\" style=\"word-spacing: -0.989px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: -0.989px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">onounced percentage point improvements in the WL</span><span class=\"_ _c\" style=\"word-spacing: -0.989px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: -0.989px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">Q from baseline to week 52 were seen in the mental domains of time management, output </span></div><span class=\"ws20\"><div style=\"text-align: justify;\"><span style=\"word-spacing: -0.943px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">demands, and mental-interpersonal demands (–38.4,</span><span class=\"_ _2\" style=\"word-spacing: -0.943px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: -0.943px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"> –37.6, and –35.4,</span><span class=\"_ _2\" style=\"word-spacing: -0.943px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: -0.943px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"> respectively; all p&lt;0.0001 vs. baseline).</span><span class=\"_ _c\" style=\"word-spacing: -0.943px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: -0.943px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">  After 52 weeks of vortioxetine treatment,</span><span class=\"_ _2\" style=\"word-spacing: -0.943px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: -0.943px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"> improvements </span></div><span class=\"ws21\"><div style=\"text-align: justify;\"><span style=\"word-spacing: 2.369px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">in all WL</span><span class=\"_ _2\" style=\"word-spacing: 2.369px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: 2.369px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">Q domains showed strong correlations with impr</span><span class=\"_ _2\" style=\"word-spacing: 2.369px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: 2.369px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">ovement in WP</span><span class=\"_ _2\" style=\"word-spacing: 2.369px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: 2.369px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">AI presenteeism (r</span><span class=\"_ _c\" style=\"word-spacing: 2.369px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: 2.369px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">, 0.54 to 0.61); </span><span class=\"fs10 ls5 ws1d v6\" style=\"-webkit-text-stroke: 0.015em transparent;\">§</span><span style=\"word-spacing: 2.369px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">Primary endpoint noninferiority was established* and </span></div><span class=\"ws22\"><div style=\"text-align: justify;\"><span style=\"word-spacing: 0.736px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">vortio</span><span class=\"_ _2\" style=\"word-spacing: 0.736px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: 0.736px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">xetine (n=252) was superior to agomelatine (n=241) by 2.2 MADRS points (p&lt;0.01); </span><span class=\"fs10 ls5 ws1d v6\" style=\"-webkit-text-stroke: 0.015em transparent;\">#</span><span style=\"word-spacing: 0.736px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">At week 8, pa</span><span class=\"_ _2\" style=\"word-spacing: 0.736px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: 0.736px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">tients (n=143) had improved by -29.8 points (p&lt;0.0001) in </span></div><span class=\"ws23\"><div style=\"text-align: justify;\"><span style=\"word-spacing: 0px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">ODQ total score,</span><span class=\"_ _2\" style=\"word-spacing: 0px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: 0px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"> and 50% reported no emotional blunting to standardised scr</span><span class=\"_ _2\" style=\"word-spacing: 0px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\"></span><span style=\"word-spacing: 0px; letter-spacing: -0.23px; -webkit-text-stroke: 0.015em transparent;\">eening question.</span></div></span></span></span></span></span></div>",
	"kja6ijk3Text": "AtWoRC,<span class=\"_ _2\"></span> Assessment in W<span class=\"_ _c\"></span>ork productivity and the Relationship with Cognitive symptoms.",
	"kja6ijk4Text": "CONNECT Study<span class=\"_ _0\"></span><span class=\"fs11 ls5 v2\">†</span>",
	"kja6ijk5Text": "AtW<span class=\"_ _c\"></span>oRC Study<span class=\"_ _0\"></span><span class=\"fs11 ls5 v2\">‡</span>",
	"kja6ijk6Text": "<div style=\"line-height: 1.3;\"><div style=\"text-align: center;\">Mean dose</div><div style=\"text-align: center;\"><span style=\"font-family: &quot;2_ANALJY+AvenirNextLTPro-Demi&quot;; font-size: 50px;\">16 mg/day</span><br></div><div style=\"text-align: center;\"><span style=\"text-align: start;\">at week 8</span><span class=\"fs8 ls5 v4\" style=\"text-align: start;\">1</span></div></div>",
	"kja6ijk9Text": "REVIV<span class=\"_ _0\"></span>E Study<span class=\"_ _2\"></span><span class=\"fs11 ls5 v2\">§</span>",
	"kja6ijkaText": "COMP<span class=\"_ _2\"></span>LETE Study<span class=\"fs11 ls5 v2\">#</span>",
	"kja6ijkbText": "<div style=\"text-align: right;\">SERT</div><div style=\"text-align: right;\">occupancy<br></div>",
	"kja6ijkdText": "<div style=\"line-height: 1.3;\"><div style=\"text-align: center;\">Mean dose</div><div style=\"text-align: center;\"><span style=\"font-family: &quot;2_ANALJY+AvenirNextLTPro-Demi&quot;; font-size: 50px;\">15.2 mg/day</span><br></div><div style=\"text-align: center;\"><span style=\"text-align: start;\">at week 52</span><span class=\"fs8 ls5 v4\" style=\"text-align: start;\">2</span></div></div>",
	"kja6ijkgText": "<div style=\"text-align: center;\">64.7%</div><div style=\"text-align: center;\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;; font-size: 32px;\">of patients ended on</span><br></div><div style=\"text-align: center;\"><span style=\"text-align: start;\">20 mg/day</span><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;; font-size: 32px;\"><br></span></div><div style=\"text-align: center;\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;; font-size: 32px; text-align: start;\">at week 5</span><span class=\"fs8 ls5 v4\" style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;; font-size: 16px; text-align: start;\">3</span><span style=\"text-align: start;\"><br></span></div>",
	"kja6ijkkText": "<div style=\"text-align: center;\">50%</div><div style=\"text-align: center;\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;; font-size: 32px;\">of patients ended on</span><br></div><div style=\"text-align: center;\"><span style=\"text-align: start;\">20 mg/day</span><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;; font-size: 32px;\"><br></span></div><div style=\"text-align: center;\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;; font-size: 32px; text-align: start;\">at week 8</span><span class=\"fs8 ls5 v4\" style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;; font-size: 16px; text-align: start;\">4</span><span style=\"text-align: start;\"><br></span></div>",
	"kja6ijkoText": "10<span class=\"_ _1\"></span>-<span class=\"_ _0\"></span>2<span class=\"_ _1\"></span>0<span class=\"_ _1\"></span> m<span class=\"_ _0\"></span>g<span class=\"_ _13\"> </span>10<span class=\"_ _1\"></span>-<span class=\"_ _0\"></span>2<span class=\"_ _1\"></span>0<span class=\"_ _1\"></span> m<span class=\"_ _0\"></span>g<span class=\"_ _14\"> </span>10<span class=\"_ _1\"></span>-<span class=\"_ _0\"></span>2<span class=\"_ _1\"></span>0<span class=\"_ _1\"></span> m<span class=\"_ _0\"></span>g<span class=\"_ _14\"> </span>10<span class=\"_ _1\"></span>-<span class=\"_ _0\"></span>2<span class=\"_ _1\"></span>0<span class=\"_ _1\"></span> m<span class=\"_ _0\"></span>g",
	"kja6ijkpText": "P<span class=\"_ _2\"></span>rescribe<span class=\"_ _15\"> </span>Pharmacokinetic<span class=\"_\"> </span>P<span class=\"_ _2\"></span>resentation<span class=\"_ _16\"></span><span class=\"ff1 fc3 wsb\">High dose</span>",
	"Brintellix_600c62379f": "<span class=\"ff1 fc0 fsb\">Brintellix<sup style=\"font-size:70%; line-height:0;\">®</sup> shows a dose-related increase in SERT<sup style=\"font-size:50%; line-height:0;\">†</sup> occupancy<br>at the approved dose range<sup style=\"font-size:50%; line-height:0;\">1</sup></span>",
	"Brintellix_60d97ddf5d": "<span class=\"ff3 fc1\" style=\"font-size:14px;\"><div style=\"text-align: right;\">Serotonin</div><div style=\"text-align: right;\">transporter</div></span>",
	"Brintellix_60c54df4f6": "<span class=\"ff3 fc1\" style=\"font-size:14px;\"><div style=\"text-align: right;\">Serotonin</div><div style=\"text-align: right;\">transporter</div></span>",
	"Brintellix_6056a7b37d": "<span class=\"ff3 fc1\" style=\"font-size:14px;\">5-HT<sub>1A</sub></span>",
	"Brintellix_6079e4aa8f": "<span class=\"ff3 fc1\" style=\"font-size:14px;\">5-HT<sub>1B</sub></span>",
	"Brintellix_60fc35b3d4": "<span class=\"ff3 fc1\" style=\"font-size:14px;\">5-HT<sub>1B</sub></span>",
	"Brintellix_60cf73416e": "<span class=\"ff3 fc1\" style=\"font-size:14px;\">5-HT<sub>3</sub></span>",
	"Brintellix_609937726f": "<span class=\"ff3 fc1\" style=\"font-size:14px;\">5-HT<sub>7</sub></span>",
	"Brintellix_60af46b265": "<span class=\"ff3 fc1\" style=\"font-size:11.5px;\">Inhibitor</span>",
	"Brintellix_6078b6878e": "<span class=\"ff3 fc1\" style=\"font-size:11.5px;\">Partial Agonist</span>",
	"Brintellix_6031680142": "<span class=\"ff3 fc1\" style=\"font-size:11.5px;\">Agonist</span>",
	"Brintellix_608fe92cdf": "<span class=\"ff3 fc1\" style=\"font-size:11.5px;\">Antagonist</span>",
	"Brintellix_60dad866fc": "<div class=\"ff3 fc1\" style=\"font-size:16px; line-height:1.5;\"><span class=\"ff3 fcf\">•</span> Dose-related increase in SERT occupancy at steady-state conditions in healthy individuals<sup style=\"font-size:50%; line-height:0;\">1</sup>:\n<p class=\"fcf\" style=\"margin:0 0 0 20px;\">~50% at Brintellix<sup style=\"font-size:70%; line-height:0;\">®</sup> 5 mg</p>\n<p class=\"fc0\" style=\"margin:0 0 0 20px;\">~65% at Brintellix<sup style=\"font-size:70%; line-height:0;\">®</sup> 10 mg</p>\n<p class=\"fc1\" style=\"margin:0 0 0 20px;\">&gt;80% at Brintellix<sup style=\"font-size:70%; line-height:0;\">®</sup> 20 mg</p>\n</div>\n<div class=\"ff3 fc1\" style=\"font-size:16px; line-height:1.5;\"><span class=\"ff3 fcf\">•</span> Necessary minimum SERT occupancy for SSRI treatment of depressive episodes is greater than 80%<sup style=\"font-size:50%; line-height:0;\">2</sup></div>",
	"Brintellix_60de3bad36": "<div class=\"ff3 fc1\" style=\"font-size:11.5px; line-height:1.2; margin-bottom:10px;\"><sup>†</sup>SERT, serotonin transporter.<br><b>1.</b> Areberg J et al. 2012. <b>2.</b> Meyer JH et al. 2004.</div>",
	"Brintellix_60de53b787": "<span class=\"ff2 fc0 fs13\">References</span>",
	"Brintellix_604217ea39": "<div class=\"ff3 fc1\" style=\"font-size:15px;\"><span class=\"ff2\">1.</span>&nbsp;Mahableshwarkar AR et al. Neuropsychopharmacol 2015;40:2025-2037.</div>",
	"Brintellix_60f506c83e": "<div class=\"ff3 fc1\" style=\"font-size:15px;\"><span class=\"ff2\">2.</span>&nbsp;Chokka P et al. J Occup Environ Med 2020;62:e94-e101.</div>",
	"Brintellix_60e6b3d8f7": "<div class=\"ff3 fc1\" style=\"font-size:15px;\"><span class=\"ff2\">4.</span>&nbsp;Fagiolini A et al. J Affect Disord. 2021;283:472-479.</div>",
	"Brintellix_603a81a47a": "<div class=\"ff3 fc1\" style=\"font-size:15px;\"><span class=\"ff2\">3.</span>&nbsp;Montgomery SA et al. Hum Psychopharmacol Clin Exp 2014;29:470-482. </div>",
	"Brintellix_60317c847f": "Text",
	"Brintellix_60339f3551": "Text"
}
